论文 · 动物实验
mRNA递送过程中缓冲细胞应激实现免疫调节性白细胞介素-2治疗
Buffering cellular stress during mRNA delivery enables immunoregulatory Interleukin-2 therapy
作者:Pengwen Chen, Guanghao Hu, Yuki Nakashima, Zhining Xu, Taehun Hong, Xiwen Chen, Soichiro Kondo, Renelyn Wolters, Hiroto Yaginuma, Sosuke Takasugi, Ervin Kovács, Horacio Cabral
J Control Release · 2026年9月23日 · Chen 等 12 位作者
不需要生物学背景,多打比方
正在获取全文并生成讲解(拿不到全文就依据摘要),大约需要 30–60 秒…
已等待 0 秒
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来,每一步都标明出自原文哪里。制作大约需要 30–60 秒。
摘要Abstract
Messenger RNA (mRNA) therapeutics enable in situ production of immunoregulatory proteins. However, cellular stress induced during delivery remains an underappreciated yet critical determinant of immune outcomes. Strategies to mitigate this stress have so far been limited. Here, we harnessed the intrinsic antioxidant and anti-inflammatory activities of curcumin by conjugating it to the cationic polymer block via pH-responsive boronate ester bonds, yielding stress-buffered mRNA nanocarriers that mitigate delivery-induced cellular perturbations. The nanocarriers remain stable in serum and enable efficient cytosolic mRNA release while reducing reactive oxygen species, suppressing stress-induced cytokine expression and avoiding activation-associated immune bias. Systemic delivery of interleukin-2 (IL-2) mRNA with these nanocarriers selectively expanded regulatory T cells, spared effector T-cell activation, and reversed established colitis in mice. In contrast, delivery with conventional carriers induced cellular stress, blunted the anti-inflammatory effects of IL-2 and failed to relieve the disease. These findings establish stress buffering as a strategy to correct the delivery-induced immune bias and enable context-specific mRNA immunotherapies.
还没有查过关联研究
我会去找这篇研究之前的基础工作、做类似事情的研究,以及之后引用它的研究,并说明每篇为什么相关。